Compare CRSP & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | INDV |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.2B |
| IPO Year | 2016 | 2014 |
| Metric | CRSP | INDV |
|---|---|---|
| Price | $50.20 | $34.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 4 |
| Target Price | ★ $85.63 | $49.00 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 1.67 |
| Revenue | $289,590,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | $1,052.09 | $7.50 |
| Revenue Next Year | $273.88 | $5.07 |
| P/E Ratio | ★ N/A | $20.41 |
| Revenue Growth | ★ 9169.85 | 4.29 |
| 52 Week Low | $44.12 | $24.03 |
| 52 Week High | $70.74 | $42.81 |
| Indicator | CRSP | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 42.52 |
| Support Level | $45.61 | $33.74 |
| Resistance Level | $60.71 | $35.70 |
| Average True Range (ATR) | 2.51 | 1.15 |
| MACD | -0.48 | -0.24 |
| Stochastic Oscillator | 8.96 | 41.65 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).